The price-to-earnings ratio for Coherus Biosciences Inc (NASDAQ: CHRS) is above average at 5.59x, Company’s 36-month beta value is 1.01.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CHRS is 111.29M, and currently, short sellers hold a 29.19% ratio of that floaft. The average trading volume of CHRS on April 15, 2025 was 1.95M shares.
CHRS) stock’s latest price update
The stock price of Coherus Biosciences Inc (NASDAQ: CHRS) has jumped by 16.59 compared to previous close of 0.84. Despite this, the company has seen a gain of 18.64% in its stock price over the last five trading days. globenewswire.com reported 2025-04-14 that – $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts –
CHRS’s Market Performance
Coherus Biosciences Inc (CHRS) has experienced a 18.64% rise in stock performance for the past week, with a 5.92% rise in the past month, and a -33.70% drop in the past quarter. The volatility ratio for the week is 14.05%, and the volatility levels for the past 30 days are at 11.06% for CHRS. The simple moving average for the past 20 days is 12.42% for CHRS’s stock, with a -18.88% simple moving average for the past 200 days.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.
CHRS Trading at -2.00% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.89% of loss for the given period.
Volatility was left at 11.06%, however, over the last 30 days, the volatility rate increased by 14.05%, as shares surge +6.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.41% lower at present.
During the last 5 trading sessions, CHRS rose by +18.64%, which changed the moving average for the period of 200-days by -41.29% in comparison to the 20-day moving average, which settled at $0.8669. In addition, Coherus Biosciences Inc saw -29.38% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.39 for the present operating margin
- 0.55 for the gross margin
The net margin for Coherus Biosciences Inc stands at 0.11. The total capital return value is set at -0.63.
Based on Coherus Biosciences Inc (CHRS), the company’s capital structure generated 1.96 points at debt to capital in total, while cash flow to debt ratio is standing at -0.08. The debt to equity ratio resting at -2.04. The interest coverage ratio of the stock is -3.86.
Currently, EBITDA for the company is 60.94 million with net debt to EBITDA at -1.69. When we switch over and look at the enterprise to sales, we see a ratio of 0.96. The receivables turnover for the company is 2.4for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.21.
Conclusion
In a nutshell, Coherus Biosciences Inc (CHRS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
